Danielle Antalffy
Stock Analyst at UBS
(3.49)
# 882
Out of 5,141 analysts
200
Total ratings
47.41%
Success rate
5.6%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $24.57 | -10.46% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $32.58 | +68.82% | 14 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $140 → $120 | $74.58 | +60.90% | 15 | Feb 5, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $98.75 | -12.91% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $79.78 | +19.08% | 14 | Jan 12, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $7 → $12 | $5.40 | +122.22% | 3 | Dec 23, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $59.53 | +52.86% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $120.27 | +20.56% | 3 | Dec 23, 2025 | |
| PRCT PROCEPT BioRobotics | Initiates: Buy | $62 | $27.27 | +127.36% | 4 | Dec 12, 2025 | |
| MDT Medtronic | Maintains: Neutral | $95 → $102 | $96.86 | +5.31% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $241.89 | +65.36% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.89 | +209.52% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $15.22 | +5.12% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $73.08 | +29.99% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $21.58 | -2.69% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $504.05 | +19.04% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $242.49 | -11.75% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $8 | $8.63 | -7.30% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $22.73 | +150.77% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $112.21 | +31.90% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $366 → $370 | $380.23 | -2.69% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.98 | -24.50% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $3.53 | +23,271.10% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $35.30 | -60.34% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $73.87 | +35.37% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $14.34 | -16.32% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $38.09 | +18.14% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $185.39 | +48.34% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $3.99 | +401.25% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $5.79 | +625.39% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $8.16 | +635.29% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.64 | +2,243.75% | 1 | Sep 1, 2020 |
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $24.57
Upside: -10.46%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $32.58
Upside: +68.82%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $140 → $120
Current: $74.58
Upside: +60.90%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $98.75
Upside: -12.91%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $79.78
Upside: +19.08%
Sight Sciences
Dec 23, 2025
Maintains: Buy
Price Target: $7 → $12
Current: $5.40
Upside: +122.22%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $59.53
Upside: +52.86%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $120.27
Upside: +20.56%
PROCEPT BioRobotics
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $27.27
Upside: +127.36%
Medtronic
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $96.86
Upside: +5.31%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $241.89
Upside: +65.36%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.89
Upside: +209.52%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $15.22
Upside: +5.12%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $73.08
Upside: +29.99%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $21.58
Upside: -2.69%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $504.05
Upside: +19.04%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $242.49
Upside: -11.75%
Aug 8, 2025
Maintains: Neutral
Price Target: $16 → $8
Current: $8.63
Upside: -7.30%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $22.73
Upside: +150.77%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $112.21
Upside: +31.90%
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $380.23
Upside: -2.69%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.98
Upside: -24.50%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $3.53
Upside: +23,271.10%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $35.30
Upside: -60.34%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $73.87
Upside: +35.37%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $14.34
Upside: -16.32%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $38.09
Upside: +18.14%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $185.39
Upside: +48.34%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $3.99
Upside: +401.25%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $5.79
Upside: +625.39%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $8.16
Upside: +635.29%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.64
Upside: +2,243.75%